Keybanc raises LifeStance Health Gr price target to $13
Keybanc analyst Steve Dechert maintained an Overweight rating on LifeStance Health Gr (NASDAQ: LFST) and raised the price target to $13 from $11, indicating a positive outlook.
*this image is generated using AI for illustrative purposes only.
Keybanc analyst Steve Dechert has maintained an Overweight rating for LifeStance Health Gr (NASDAQ: LFST) while raising the price target to $13 from the previous $11. This revision signals increased confidence in the company's near-term stock performance.
The decision to upgrade the price target comes as LifeStance Health Gr continues to navigate the behavioral health market. The Overweight rating suggests that the stock is expected to outperform the broader market or its sector peers in the coming period.
Investors following LifeStance Health Gr will note that the new price target of $13 represents a specific upside from the prior target of $11. The rating and target adjustments are based on the analyst's assessment of the company's operational and financial trajectory.
Analyst Rating and Price Target
| Metric | Value |
|---|---|
| Rating | Overweight |
| Previous Price Target | $11 |
| New Price Target | $13 |
The revised target provides a clear benchmark for market participants evaluating the stock's potential. LifeStance Health Gr operates within the healthcare sector, specifically focusing on mental health services.
What specific operational milestones does LifeStance need to achieve to justify the new $13 price target?
How might current macroeconomic conditions impact patient demand for behavioral health services in the near term?
Could this rating revision trigger a broader re-rating of the behavioral health sector among institutional investors?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
